Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy

• Published in: Molecules (Basel, Switzerland) Switzerland), 2020-01, Vol.25 (2), p.333
• Main Authors: Nogueira, João, Soares, Sofia F, Amorim, Carlos O, Amaral, João S, Silva, Cláudia, Martel, Fátima, Trindade, Tito, Daniel-da-Silva, Ana L
• Format: Article
• Language: English
• Subjects: Antibiotics, Antineoplastic - chemistry; Antibiotics, Antineoplastic - pharmacology; Biopolymers; Blood; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer therapies; Carrageenan; Chemotherapy; Cores; Cytotoxicity; Doxorubicin; Doxorubicin - chemistry; Doxorubicin - pharmacology; drug carrier; Drug carriers; Drug Carriers - administration & dosage; Drug Carriers - chemistry; Drug delivery; Drug Delivery Systems; Drug Liberation; Drug resistance; Female; Humans; Hydrogen-Ion Concentration; iron oxide; Iron oxides; Magnetic Fields; magnetic nanoparticles; Metastasis; Nanomaterials; Nanoparticles; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Nanotechnology; Particle size; Permeability; ph-responsive; Polyethylene glycol; Selectivity; Shells; Side effects; Tumor Cells, Cultured; Tumor microenvironment; Vibration; κ-carrageenan
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules25020333

Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin.